Dysbiosis as a Cancer Treatment Determinant
Gut microbiota dysbiosis — defined by loss of microbial diversity, depletion of immunostimulatory species, and enrichment of immunosuppressive or oncogenic bacteria — is consistently associated with poor cancer treatment outcomes across melanoma, non-small cell lung cancer (NSCLC), colorectal cancer (CRC), renal cell carcinoma (mRCC), urothelial carcinoma, multiple myeloma, and hematological malignancies undergoing hematopoietic cell transplantation (HCT). This is no longer a hypothesis: patent filings and clinical cohort data now converge on specific microbial taxa as mechanistic drivers of treatment response and resistance.
The microbial taxa most repeatedly implicated across retrieved results span both immunostimulatory commensals and oncogenic species. Akkermansia muciniphila is identified in patent filings from INRA and INSERM as a primary commensal distinguishing immunotherapy responders from progressors, with oral gavage of A. muciniphila explicitly associated with reduced tumor size in anti-PD-1 avatar mouse models. Bifidobacterium spp. are enriched in immunotherapy responders and associated with anti-PD-L1 efficacy, while being notably depleted in mRCC patients relative to healthy adults.
On the oncogenic side, Fusobacterium nucleatum is characterized as a driver of CRC chemotherapy resistance and poor prognosis, with intratumoral presence confirmed across multiple tumor types. The emerging concept of the tumor microbiome — intratumoral bacterial communities distinct from gut microbiota — extends these implications to pancreatic, bladder, prostate, lung, and nasopharyngeal cancers, where local microbial communities modulate epithelial-mesenchymal transition (EMT) and drug response.
Short-chain fatty acids (SCFAs), particularly butyrate, are key microbial metabolites mediating immune cell proliferation, cytokine expression, and T-cell activation in the context of cancer treatment, including CAR-T therapy for non-Hodgkin lymphoma.
The gut microbiome refers to the systemic microbial community in the gastrointestinal tract that modulates systemic immunity. The tumor microbiome describes intratumoral bacteria residing within the tumor mass itself, which can directly regulate local immune exclusion, EMT-associated gene expression (E-cadherin, vimentin, SNAI2, TWIST1), and drug resistance — representing a distinct and largely unpatented therapeutic frontier.
FMT as an Oncology Adjunct: Clinical Evidence and IP Landscape
Fecal microbiota transplantation is the most extensively discussed therapeutic modality in the microbiome-oncology pipeline, with applications spanning checkpoint inhibitor potentiation, dysbiosis correction in hematological malignancies, and MDRO eradication ahead of hematopoietic cell transplantation. FMT is currently FDA-approved only for recurrent Clostridioides difficile infection, but the clinical signals for oncology applications are accumulating across multiple tumor types and treatment settings.
“FMT-treated, MDRO-colonized pre-HCT patients showed 70% 12-month survival versus 36% in untreated colonized controls — a statistically significant difference (p=0.044) in a retrospective cohort at Imperial College London’s Hammersmith Hospital.”
The most consistently described combination approach is FMT plus anti-PD-1 immune checkpoint blockade. Preclinical multi-omics data demonstrate that combining FMT with anti-PD-1 therapy in colorectal tumor-bearing mice produces superior survival rates and tumor control compared to either monotherapy, with metagenomic analysis identifying Bacteroides species as key mediators. This is clinically relevant given that anti-PD-1 non-response rates reach up to 70% in melanoma patients — a treatment gap that FMT-based microbiome restoration may partially address.
A Phase II multicenter study (NCT02928523) evaluated autologous FMT in 25 AML patients receiving intensive chemotherapy, with co-primary endpoints of dysbiosis correction and MDRO eradication, reported by CHU Saint-Antoine, Paris in 2021.
Patent filings from INRA operationalize FMT as a theranostic pre-treatment protocol: patients predicted to be ICB non-responders based on dysbiotic microbiome profiles receive FMT and/or immunogenic probiotics before ICB initiation, while predicted responders proceed directly to anti-PD-1/PD-L1 therapy. This stratified approach is explicitly claimed in multiple INRA IL-jurisdiction filings (2019). INSERM’s co-assigned EP filing with Institut Gustave Roussy extends these claims to chemotherapy responsiveness more broadly.
Lyophilized capsule-based FMT (cFMT) is discussed as a clinically viable alternative to colonoscopic delivery, reducing procedural burden in immunocompromised oncology patients. However, safety limitations in this population — particularly the risk of pathogen transfer and MDRO dissemination — remain a core constraint that next-generation probiotic consortia are positioned to address. According to the FDA, FMT products are regulated as biologics in the United States, adding regulatory complexity to oncology-specific applications.
Map the full FMT and microbiome-oncology patent landscape with PatSnap Eureka’s AI-powered drug intelligence tools.
Explore the Patent Landscape in PatSnap Eureka →Next-Generation and Engineered Probiotics in the Pipeline
Retrieved results demarcate a clear transition from traditional Lactobacillus/Bifidobacterium supplementation toward rationally designed bacterial therapeutics — a shift driven by both the safety limitations of FMT and the need for reproducible, IP-differentiated products. Next-generation probiotics (NGPs) including Akkermansia muciniphila, Faecalibacterium prausnitzii, and non-toxigenic Bacteroides fragilis are discussed as agents that enhance gastrointestinal immunity, maintain barrier integrity, produce immunomodulatory metabolites, and improve immunotherapy efficacy.
INSERM’s patent portfolio is the most active in this space, claiming Lactobacillus johnsonii (strain CNCM 1-4823), Enterococcus hirae (strain CNCM 1-4815), and Enterococcus faecalis as immunogenic probiotic strains capable of inducing T-bet/Th1-polarized immune responses in combination with antineoplastic agents, including adoptive T-cell transfer protocols. This mechanistic framing — immune polarization as a patentable endpoint — represents a significant IP claim scope that drug developers must assess for freedom-to-operate.
Bacteria-mediated synergistic cancer therapy (BMSCT) platforms — including engineered Salmonella typhimurium VNP20009, which failed Phase I due to low tumor regression — are evolving toward combination strategies. Next-generation approaches including GEN-001 are identified as active areas in retrieved literature, with the field pivoting to pair direct antitumor delivery with microbiome-mediated immunomodulation.
Seed Health Inc. has filed a pending IL patent (2023) claiming rationally assembled microbial consortia combined with punicalagin-containing prebiotic components for microbiome reconstitution post-broad-spectrum antibiotic therapy, with reference to clinical trial NCT04171466. This synbiotic formulation approach — combining defined consortia with specific prebiotics — represents a commercially differentiated strategy relative to single-strain probiotics.
Pilot clinical evidence is emerging for specific probiotic interventions: a pilot randomized trial in NS-NSCLC patients receiving bevacizumab plus platinum-based chemotherapy found significantly increased Clostridium, Bifidobacterium, and Lactobacillus abundance in the Clostridium butyricum probiotic arm, with assessed effects on progression-free and overall survival. A separate Phase II randomized trial in nasopharyngeal carcinoma enrolled 77 patients to evaluate probiotic cocktail versus placebo during concurrent chemoradiotherapy, with grade 3+ oral mucositis incidence as the primary endpoint. According to the WHO, oral mucositis affects a substantial proportion of patients undergoing chemoradiotherapy and represents a significant quality-of-life burden.
INSERM patents claim Lactobacillus johnsonii (strain CNCM 1-4823) and Enterococcus hirae (strain CNCM 1-4815) as immunogenic probiotic strains that induce T-bet/Th1 immune responses in combination with antineoplastic agents, including adoptive T-cell transfer protocols — representing active IL-jurisdiction filings from 2016 to 2019.
The intersection of microbiome biology and CAR-T cell therapy represents an emerging frontier: one retrieved abstract examines gut microbiota diversity and butyrate-producing bacteria as modulators of CD19 CAR-T efficacy and toxicity in non-Hodgkin lymphoma, linking SCFA-producing commensals to adoptive cell therapy outcomes. This convergence is particularly relevant for hematology-oncology indications where both dysbiosis and CAR-T-related toxicity are concurrent clinical challenges. Research published through Nature has increasingly documented the mechanistic links between butyrate-producing bacteria and T-cell function.
Microbiome Biomarker-Guided Checkpoint Potentiation
A distinct and commercially significant modality in this dataset involves using microbiome composition as a theranostic tool — simultaneously guiding patient selection for immune checkpoint blockade and directing microbiome-targeted pre-treatment interventions. Machine-learning models trained on whole-metagenome shotgun sequencing data achieve AUC values up to 95–100% in predicting NSCLC immunotherapy benefit (progression-free survival greater than six months versus less than three months), using random forest and multilayer perceptron classifiers — though dataset sizes are noted as small in retrieved results.
“Machine-learning models using whole-metagenome shotgun sequencing achieve AUC values up to 95–100% in predicting NSCLC immunotherapy benefit — but the field awaits validation in larger, prospectively enrolled cohorts before these models can guide clinical decision-making.”
The University of Chicago holds an active EP-jurisdiction patent (2024) covering microbiome biomarkers of immunotherapy responsiveness with broad claims spanning diagnostic, prognostic, and therapeutic applications. The patent specifies bacterial taxa including Ruminococcaceae, Lachnospiraceae, Bifidobacteriaceae, Clostridiaceae, and Enterobacteriaceae as diagnostic and therapeutic targets — a claim scope that encompasses both companion diagnostic and microbiome manipulation strategies.
The Bacteroidota/Firmicutes ratio is reported as a predictive biomarker for anti-PD-1 response in melanoma cohorts across multiple independent patient populations. A study from Poznan University of Medical Sciences in Polish melanoma patients demonstrates that gut microbiome composition mediates clinical outcomes of anti-PD-1 therapy — a finding with population-specific implications given that microbiome composition varies substantially across geographic and dietary contexts, as documented by WIPO-tracked international research collaborations.
Identify microbiome biomarker patent white space and freedom-to-operate risks with PatSnap Eureka’s AI drug intelligence platform.
Analyse Microbiome IP in PatSnap Eureka →Pharmacomicrobiomics: Chemotherapy’s Bidirectional Microbiome Relationship
Pharmacomicrobiomics describes the bidirectional relationship in which gut bacteria modify chemotherapy pharmacokinetics and pharmacodynamics, while chemotherapy reciprocally disrupts microbiome composition — creating a feedback loop with direct implications for treatment efficacy and toxicity management. Retrieved results across multiple tumor types and chemotherapy regimens document both directions of this relationship with increasing mechanistic specificity.
Fusobacterium nucleatum is the most extensively characterized oncogenic microbe in this context: its abundance in CRC is linked to chemotherapy resistance through multiple mechanisms, correlates with proximal tumor location and adverse prognosis, and has been detected in intratumoral contexts. Conversely, probiotic supplementation with Clostridium butyricum, Lactobacillus casei Shirota, and Bifidobacterium breve enhances anti-tumor immune responses in gemcitabine/cisplatin-treated urothelial carcinoma mouse models — demonstrating that microbiome modulation can augment chemotherapy efficacy.
Bacteroides ovatus and Bacteroides xylanisolvens are positively correlated with multi-cancer treatment outcomes in machine-learning metagenomic models, and oral gavage of these species increases erlotinib efficacy in preclinical models — extending pharmacomicrobiomics to targeted therapy beyond immunotherapy.
The Simulator of Human Intestinal Microbial Ecosystem (SHIME) model is used in retrieved results to demonstrate protective effects of Lactobacillus/Bifidobacterium blends against 5-fluorouracil-mediated dysbiosis in vitro — providing a mechanistic tool for screening probiotic interventions before clinical translation. In nasopharyngeal carcinoma, a Phase II randomized clinical trial provides the strongest clinical evidence for probiotics as a chemotherapy adjunct: 77 patients randomized to probiotic cocktail versus placebo during concurrent chemoradiotherapy, with grade 3+ oral mucositis as the primary endpoint.
An underexplored dimension highlighted in retrieved results is pediatric oncology pharmacomicrobiomics. One review explicitly notes that the gut microbiome in pediatric oncological patients influences drug pharmacokinetics, treatment efficacy, and clinical outcomes, and that this population presents distinct microbiome dynamics from adults — signaling a potentially underserved clinical and IP space. The NIH has flagged pediatric microbiome research as a priority area given the distinct developmental biology of the pediatric gut.
Strategic IP Implications and White Space
The assignee landscape in this dataset is concentrated in a small number of French public research institutes and one major U.S. academic institution, creating a patent environment with specific freedom-to-operate considerations for drug developers entering the microbiome-oncology space. INSERM is the most active patent assignee, holding multiple active IL-jurisdiction filings (2016–2019) and an EP filing co-assigned with Institut Gustave Roussy, covering microbiota composition as a chemotherapy responsiveness marker and defined probiotic strains as cancer treatment adjuvants.
Core patents on FMT plus anti-PD-1 combinatorial use are held primarily by INSERM and INRA, with the University of Chicago’s 2024 EP patent covering biomarker-guided stratification with broad claim scope spanning diagnostic, prognostic, and therapeutic applications. Drug developers should assess freedom-to-operate for FMT pre-treatment protocols in ICB combinations, particularly in jurisdictions covered by active INSERM/Gustave Roussy EP filings.
Retrieved results from bladder carcinoma, prostate cancer, nasopharyngeal carcinoma, and lung cancer implicate intratumoral bacterial communities — distinct from gut microbiota — in EMT, local immune regulation, and drug resistance. Therapeutic strategies targeting the tumor microbiome directly represent an emerging and largely unpatented frontier visible in this dataset, distinct from the more crowded gut microbiome modulation space.
Next-generation probiotic consortia with defined compositions represent a lower-regulatory-risk, IP-differentiated alternative to FMT — particularly relevant for hematology-oncology indications including HCT and CAR-T settings where FMT’s safety limitations are most acute. Seed Health Inc.’s 2023 synbiotic patent (defined consortia plus punicalagin prebiotic) exemplifies this differentiation strategy. Microbiome stratification as a companion diagnostic opportunity is also emerging: paired IVD/CDx development alongside microbiome therapeutics could represent a commercially defensible integrated diagnostic-therapeutic strategy, consistent with regulatory frameworks being developed by agencies including the EMA for companion diagnostics in oncology.
The convergence of tumor microbiome and systemic microbiome research represents the most strategically significant emerging direction: as intratumoral bacteria are implicated in EMT-associated gene expression (E-cadherin, vimentin, SNAI2, SNAI3, TWIST1) in muscle-invasive bladder carcinoma, the therapeutic opportunity extends beyond gut modulation to direct tumor microenvironment intervention — a frontier with minimal existing IP coverage in this dataset.